OIPE 428

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO 09/662784-Conf. #3152 Application Number INFORMATION DISCLOSURE September 15, 2000 Filing Date STATEMENT BY APPLICANT First Named Inventor Malcolm L. GEFTER Art Unit 1649 (Use as many sheets as necessary) Examiner Name S. L. Turner 2 IMI-044DV3CNRCE2 Sheet of Attorney Docket Number

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
ST	A1	4,163,778	08-07-1979	Ohman et al.	

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY			T⁵	
ST.	B1	WO-91/06571-A1	05-16-1991	Immulogic Pharmaceutical Corporation		П	
ST	B2	WO-93/08280-A1	04-29-1993	Immulogic Pharmaceutical Corporation			
ST	В3	WO-93/19178-A2	09-30-1993	Immunologic Pharmaceutical Corporation			
ST	B4	WO-92/15613-A1	09-17-1992	Immunologic Pharmaceutical Corporation			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.qov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
ST	C1	Anderson, M.C. et al., "A comparative study of the allergens of cat urine, serum, saliva, and pelt," J. Allergy Clin Immunol, Vol. 76:563-569 (1985)			
ST	C2	Burgess, W. H. et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," The Journal of Cell Biology, Vol. 111:2129-2138 (1990)			
ST	СЗ	Chapman, M. D. et al., "Monoclonal Antibodies to the Major Feline Allergen fel d I, II. Single Step Affinity Purification of Fel d I, N-Terminal Sequence Analysis, and Development of a Sensitive Two-Site Immunoassay to Assess Fel d I Exposure," The Journal of Immunology, Vol. 140(3):812-818 (1988)			
ST	C4	de Groot, H. et al., "Monoclonal antibodies to the major feline allergen Fel d I," J Allergy Clin Immunol, Vol. 82:778-786 (1988)			
ST	C5	Didierlaurent, A. et al., "Comparative Study on Cat Allergens from Fur and Saliva," Int. Archs Allergy appl. Immun., Vol. 73:27-31 (1984)			
ST	C6	Duffort, O. et al., "Monoclonal antibodies against Fel d I and other clinically relevant cat allergens," Immunology Letters, Vol. 17:71-77 (1988)			
ST	C7	Duffort, O. et al., "Characterization of the Main IgE-Binding Components of Cat Dander," Int. Archs Allergy appl. Immun., Vol. 84:339-344 (1987)			
ST	C8	Jenkins, M.K. et al., "Antigen Presentation by Chemically Modified Splenocytes Induces Antigen-Specific T Cell Unresponsiveness In Vitro and In Vivo," Journal of Experimental Medicine, Vol. 165:302-319 (1987)			

Examiner	/Chaman/	· Date	05/08/2006
Signature	/Sharon Turner/	Considered	05/08/2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			*	Complete if Known		
				Application Number	09/662784-Conf. #3152	
l IN	NFORMATIO	N DISC	LOSURE	Filing Date	September 15, 2000	
S	TATEMENT	BY AP	PLICANT	First Named Inventor	Malcolm L. GEFTER	
			•	Art Unit	1649	
	(Use as many sheets as necessary)			Examiner Name	S. L. Turner	
Sheet	2	of	2	Attorney Docket Number	IMI-044DV3CNRCE2	

C9 Kumar, V. et al., "Amino acid variations at a single residue in an autoimmune profoundly affect its properties: T-cell activation, major histocompatibility com ability to block experimental allergic encephalomyelitis," <i>Proc. Natl. Acad. Sci.</i> 87:1337-1341 (1990)	
ST C10 Lazar, E. et al., "Transforming Growth Factor α: Mutation of Aspartic Acid 47 Results in Different Biological Activities," Molecular and Cellular Biology, Vol. (1988)	. 8(3):1247-1252
ST C11 Leitermann, K. et al., "Cat allergen 1: Biochemical, antigenic, and allergenic particles Allergy Clin Immunol, Vol. 74:147-153 (1984)	
ST C12 Lerner, R.A., "Tapping the immunological repertoire to produce antibodies of specificity," <i>Nature, Vol.</i> 299:592-596 (1982)	
ST C13 Løwenstein, H. et al., "Identification and Clinical Significance of Allergenic Mo Origin," Allergy, Vol. 40:430-441 (1985)	
ST C14 Margalit, H. et al., "Prediction of Immunodominant Helper T Cell Antigenic Sit Primary Sequence," The Journal of Immunology, Vol. 138(7):2213-2229 (198	37)
C15 Mester, J.C. et al., "The Mouse Model and Understanding Immunity to Herpes Reviews of Infectious Diseases, Vol. 13(Suppl. 11):S935-945 (1991)	
C16 Ohman, J. L. et al., "Allergens of Mammalian Orgin, III. Properties of a Major The Journal of Immunology, Vol. 113(6):1668-1677 (1974)	,
ST C17 Ohman, J.L. et al. "Immunotherapy in cat-induced asthma. Double-blind trial in vivo and in vitro responses," J Allergy Clin Immunol, Vol. 74:230-239 (1984)	
C18 Pongor, S. "The USe of Structural Profiles and Parametric Sequence Comparts Rational Design of Polypeptides," <i>Methods in Enzymology, Vol.</i> 154:450-473	
ST Salgaller, M.L. et al., "Generation of specific anti-melanoma reactivity by stim tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide," Cancer Immun Immunotherapy, Vol. 39:105-116 (1994)	nology
Stone, K. L. et al., "Enzymatic Digestion of Proteins and HPLC Peptide Isolati Guide to Protein and Peptide Purification for Microsequencing, Second Editio (1993)	
C21 Sundin, B. et al., "Immunotherapy with partially purified and standardized anim extracts," J Allergy Clin Immunol, Vol. 77:478-487 (1986)	
C22 Ununue, "Immediate Hypersensitivity Reactions and Anaphylaxis," Chapter 1- Immunology, 2nd Edition, pp. 281-298 (1984)	
van Milligen, F.J. et al., "IgE Epitopes of the Cat Allergen Fel d I; A Study with Synthetic Peptides," CLB and Lab Exp. Clin. Immunol., Univ. of Amsterdam, A 89(1, part 2):243 (1982)	Abstracts, Vol.
C24 Young, R.A. et al., "Efficient isolation of genes by using antibody probes," Pro Sci. USA, Vol. 80:1194-1198 (1983)	oc. Natl. Acad.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner I		Date	
		Date	
Signature	/Sharon Turner/	Considered	05/08/2006
Olginature	/DMGION INTHET/	Considered	03/00/2000

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.